DE60311825D1 - Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung - Google Patents

Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung

Info

Publication number
DE60311825D1
DE60311825D1 DE60311825T DE60311825T DE60311825D1 DE 60311825 D1 DE60311825 D1 DE 60311825D1 DE 60311825 T DE60311825 T DE 60311825T DE 60311825 T DE60311825 T DE 60311825T DE 60311825 D1 DE60311825 D1 DE 60311825D1
Authority
DE
Germany
Prior art keywords
kappa
inhibitors
treatment
presenter
breast
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60311825T
Other languages
English (en)
Other versions
DE60311825T2 (de
Inventor
Delphine Boulanger
Fabrice Bureau
Pierre Lekeux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE60311825D1 publication Critical patent/DE60311825D1/de
Application granted granted Critical
Publication of DE60311825T2 publication Critical patent/DE60311825T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE60311825T 2002-08-14 2003-08-12 Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung Expired - Fee Related DE60311825T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02078352 2002-08-14
EP02078352 2002-08-14
PCT/EP2003/050373 WO2004016253A1 (en) 2002-08-14 2003-08-12 Use of nf-kappa b inhibitors for the treatment of mastitis

Publications (2)

Publication Number Publication Date
DE60311825D1 true DE60311825D1 (de) 2007-03-29
DE60311825T2 DE60311825T2 (de) 2007-12-06

Family

ID=31725450

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60311825T Expired - Fee Related DE60311825T2 (de) 2002-08-14 2003-08-12 Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung

Country Status (10)

Country Link
US (1) US20060240011A1 (de)
EP (1) EP1536777B1 (de)
JP (1) JP2005539028A (de)
AT (1) ATE353638T1 (de)
AU (1) AU2003271747B2 (de)
CA (1) CA2495068A1 (de)
DE (1) DE60311825T2 (de)
DK (1) DK1536777T3 (de)
ES (1) ES2282658T3 (de)
WO (1) WO2004016253A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004021281A1 (de) * 2004-04-29 2005-11-24 Boehringer Ingelheim Vetmedica Gmbh Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
WO2015000022A1 (en) * 2013-07-05 2015-01-08 Adelaide Research & Innovation Pty Ltd Treatment and prevention of mastitis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2366877A1 (en) * 1999-03-22 2000-09-28 Stanley Michael Roberts Chemical compounds and their uses
GB9922505D0 (en) * 1999-09-24 1999-11-24 Kennedy Rheumatology Inst Therapeutic methods and compounds

Also Published As

Publication number Publication date
AU2003271747A1 (en) 2004-03-03
JP2005539028A (ja) 2005-12-22
EP1536777B1 (de) 2007-02-14
WO2004016253A1 (en) 2004-02-26
ATE353638T1 (de) 2007-03-15
DK1536777T3 (da) 2007-06-04
EP1536777A1 (de) 2005-06-08
DE60311825T2 (de) 2007-12-06
CA2495068A1 (en) 2004-02-26
ES2282658T3 (es) 2007-10-16
US20060240011A1 (en) 2006-10-26
AU2003271747B2 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
TW200626068A (en) Active compounds for seed treatment
MY151032A (en) Treatment of tnf? related disorders
EA200700851A1 (ru) Получение и применение бифенил-4-илкарбониламинокислотных производных для лечения ожирения
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
ATE323490T1 (de) Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
DE60139466D1 (de) Behandlung von diabetes
DE60105025D1 (de) Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE60328603D1 (de) Prodrugs von imidazol-derivaten, zur verwendung als protonenpumpen-hemmer zur behandlung von z.b. peptischen magengeschwüren
DE60312969D1 (de) Zubereitung für die wundheilung und zur verhinderung des anhaftens von verbänden an die wunde
DE60329326D1 (de) Tace inhibitoren
ATE290384T1 (de) Etherlysophospholipide zur behandlung von chronischen entzündlichen erkrankungen
TW200600084A (en) Anti-coronavirus compounds
ATE406171T1 (de) Aplidine zur behandlung von multiplem myelom
SE0002739D0 (sv) New use
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60311825D1 (de) Verwendung von nf-kappa b hemmern zur behandlung von brustdrüsenentzündung
SE0200198D0 (sv) New use
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
DE60330233D1 (de) Arsentherapie zur behandlung von autoimmunerkrankungen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee